Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will focus its biosimilar development and partnering activities on the U.S. market and discontinue its biosimilar programs in the rest of the world.
Spokesperson Susan Holz told BioCentury that Boehringer's first U.S. priority is
